London, UK – June 6, 2025 – Mitotech Ltd., a clinical-stage biotechnology company focused on mitochondria-based therapies, will present new results in animal models of obesity for its investigational compound MT-1101 at Obesity Science & Innovation 2025. The inaugural conference, held September 16-17, 2025, in Boston, MA, is a specialized event where industry leaders converge to accelerate the development and commercialization of obesity therapeutics.
“Our latest findings in large non-rodent animal models show that once-daily oral treatment with MT-1101 can reduce body weight by up to 27%,” said Natalia Perekhvatova, CEO of Mitotech Ltd. “We’re excited to share this promising development, which highlights MT-1101’s potential as both a standalone treatment for obesity and a maintenance option following the discontinuation of GLP-1 agonists. With its unique and complementary mechanism of action, we believe Mitotech’s approach could significantly advance the treatment of metabolic disorders.
MT-1101 is a mild mitochondrial uncoupler that promotes lipid disposal and inhibits ferroptosis—a form of programmed cell death linked to oxidative stress. Recent preclinical studies have shown that MT-1101 can improve metabolic function and reduce fat accumulation, while preserving muscle mass in high-fat diet (HFD) obesity models. These results add to the growing body of evidence supporting MT-1101 as a promising therapeutic candidate for obesity and related complications, including metabolic dysfunction-associated steatohepatitis (MASH).
At the Obesity Science & Innovation 2025 meeting, Mitotech’s COO, Dr. Anton Petrov, will present data from a series of animal studies with MT-1101, highlighting the following key findings:
- A highly significant 27% reduction in body weight in a large non-rodent animal model.
- Effective protection of muscle mass during MT-1101-induced weight loss.
- Enhanced weight loss efficacy when MT-1101 is combined with GLP-1 agonist treatment, showing greater results than either treatment alone.
- Robust weight maintenance after discontinuation of GLP-1 agonists (semaglutide and tirzepatide)..
For more information about Mitotech Ltd. and MT-1101, please visit www.mitotechpharma.com or contact:
Anton Petrov
info@mitotechpharma.com
About Mitotech Ltd.
Mitotech Ltd. is a clinical-stage biotechnology company dedicated to developing mitochondria-targeted therapies for the treatment of complex, chronic diseases. With a focus on mitochondrial dysfunction, lipid metabolism, oxidative stress, and cell survival mechanisms, Mitotech is advancing a pipeline of novel drug candidates aimed at improving patient outcomes in diseases such as obesity, cardiovascular and autoimmune disorders, and neurodegenerative diseases.
About Obesity Science & Innovation 2025
Obesity Science & Innovation 2025 conference is the inaugural event focused on the development and commercialization of novel obesity treatments. Organized by Informa Connect, the conference will bring together leading scientists, clinicians, and drug development experts to share the latest research, clinical insights, and innovations aimed at accelerating the development and commercialization of obesity therapeutics.